Inclusive
7078
Renascience
4889
Chordia Therapeutics
190A
Kufu Company Holdings
4376
Cube
7112
(Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 0.89%2.16B | -0.31%2.12B | -0.56%8.48B | -0.32%2.11B | -1.40%2.1B | 0.86%2.14B | -1.36%2.12B | -12.73%8.53B | -2.42%2.12B | -12.50%2.13B |
Cost of revenue | -1.81%1.07B | 0.80%1.07B | 4.97%4.48B | 6.92%1.17B | 2.05%1.16B | 6.25%1.09B | 4.81%1.07B | -30.20%4.27B | -12.02%1.09B | -25.21%1.13B |
Gross profit | 3.68%1.09B | -1.42%1.04B | -6.08%4.01B | -7.98%949.02M | -5.34%944.71M | -4.16%1.05B | -6.88%1.06B | 16.40%4.27B | 10.30%1.03B | 8.47%997.95M |
Operating expense | -4.50%965.92M | -7.89%955.62M | -7.19%3.78B | -13.08%874.91M | -10.96%857.46M | -2.20%1.01B | -3.06%1.04B | 3.19%4.07B | -20.30%1.01B | 18.40%963.06M |
Operating profit | 194.77%127.66M | 333.97%86.8M | 17.44%224.66M | 199.58%74.11M | 150.03%87.24M | -34.72%43.31M | -69.38%20M | 167.38%191.3M | 107.54%24.74M | -67.28%34.89M |
Net non-operating interest income (expenses) | -33.77%-610K | -6.75%-490K | 19.41%-1.88M | 6.55%-499K | 15.86%-467K | 15.08%-456K | 35.17%-459K | 67.73%-2.33M | 31.10%-534K | 29.12%-555K |
Non-operating interest income | --0 | 0.00%1K | 50.00%3K | --0 | 100.00%2K | --0 | 0.00%1K | -93.55%2K | 13.04%-40K | -96.67%1K |
Non-operating interest expense | 33.77%610K | 6.74%491K | -19.35%1.88M | 1.01%499K | -15.65%469K | -20.97%456K | -35.12%460K | -67.84%2.34M | -32.24%494K | -31.61%556K |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | -0.92%-547K | -27.71%-4.77M | -281.66%-5.38M | -105.24%-554K | 19.97%-549K | 20.06%-542K | 40.20%-3.73M | 103.73%2.96M | 114.78%10.57M | 89.32%-686K |
Income from associates and other participating interests | -12.39M | |||||||||
Special income (charges) | 135.61%999K | 2,149.47%6.41M | -80.05%2.48M | -87.22%1.36M | -24.68%409K | -24.69%424K | -58.45%285K | 236.48%12.41M | 263.97%10.62M | 134.83%543K |
Less:Other special charges | --0 | -943.37%-5.66M | 113.15%912K | --241K | --0 | --0 | --671K | -322.42%-6.94M | ---- | ---- |
Less:Write off | -135.61%-999K | 21.34%-752K | 38.16%-3.39M | 56.63%-1.6M | 24.68%-409K | 24.69%-424K | -39.36%-956K | -191.65%-5.48M | -156.92%-3.69M | -171.50%-543K |
Other non-operating income (expenses) | -54.30%85K | -87.38%167K | -16.54%1.74M | -58.47%49K | 232.73%183K | 47.62%186K | -25.97%1.32M | 582.87%2.09M | 281.54%118K | 121.24%55K |
Income before tax | 197.27%127.59M | 405.86%88.13M | 7.36%221.62M | -29.36%74.46M | 297.17%86.82M | -1.78%42.92M | -50.87%17.42M | 148.88%206.43M | 124.39%105.41M | -72.90%21.86M |
Income tax | -391.67%-10.64M | 144.02%15.74M | -286.63%-19.54M | 73.81%-7.93M | 95.29%20.51M | -58.35%3.65M | -266.40%-35.77M | 112.87%10.47M | -4,444.62%-30.28M | 962.78%10.5M |
Net income | 251.97%138.23M | 36.09%72.38M | 23.07%241.17M | -39.28%82.39M | 483.77%66.32M | 12.40%39.27M | 280.88%53.19M | 145.86%195.96M | 131.35%135.7M | -86.12%11.36M |
Net income continuous operations | 251.98%138.23M | 36.09%72.38M | 23.07%241.16M | -39.28%82.39M | 483.77%66.32M | 12.40%39.27M | 280.85%53.19M | 145.86%195.96M | 131.35%135.69M | -86.12%11.36M |
Noncontrolling interests | 0 | |||||||||
Net income attributable to the company | 251.97%138.23M | 36.09%72.38M | 23.07%241.17M | -39.28%82.39M | 483.77%66.32M | 12.40%39.27M | 280.88%53.19M | 150.43%195.96M | 131.35%135.7M | -86.12%11.36M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 251.97%138.23M | 36.09%72.38M | 23.07%241.17M | -39.28%82.39M | 483.77%66.32M | 12.40%39.27M | 280.88%53.19M | 150.43%195.96M | 131.35%135.7M | -86.12%11.36M |
Gross dividend payment | ||||||||||
Basic earnings per share | 250.27%12.82 | 35.69%6.73 | 23.04%22.48 | -39.29%7.68 | 483.02%6.18 | 12.27%3.66 | 281.54%4.96 | 150.44%18.27 | 131.35%12.65 | -86.11%1.06 |
Diluted earnings per share | 250.00%12.81 | 35.08%6.7 | 22.17%22.32 | -39.29%7.68 | 483.55%6.18 | 12.37%3.66 | 281.54%4.96 | 150.44%18.27 | 131.35%12.65 | -86.12%1.059 |
Dividend per share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |